Similarly, antagonists of TLR7 and TLR9, which are overexpressed in MG thymus and contribute to IFN and autoantibody production, have demonstrated efficacy in ameliorating disease in experimental autoimmune models (99). This evidence concerns the gene TLR9 and myasthenia gravis.